Europacific Growth Fund Lends Over 100 Million Euros in Grifols Shares

Europacific Growth Fund, legal owner of Grifols shares, has lent more than 100 million euros in shares of the blood products firm, which amounts to a total amount of 13.1 million shares, according to the documentation contained in the National Securities Market Commission (Cnmv).

Specifically, Europacific Growth Fund, which has reduced its participation in Grifols’ capital from 3.4% to 3.2%, distributes its position in the Spanish firm between 0.14% of voting rights attributed to the shares and 3.07% through financial instruments, which were notified to the supervisor last Friday, March 15th.

The latest registered notification also shows that the percentage of voting rights attributed to the shares has decreased from 2.25% (9.6 million shares) to 0.14% (631,807 shares), reflecting that Europacific Growth Fund has disposed of a package of 8,972,419 Grifols shares, valued at more than 69 million euros based on current market prices.

For its part, Europacific Growth Fund has increased its voting rights through instruments from 1.19% (5.1 million shares), notified on March 11, to 3.07% (13.1 million shares). financial, or rights to withdraw borrowed ordinary shares, which reflects that the entity has transferred more than 100 million euros in securities of the Catalan company.

Read more about the selling of Grifols shares by the Europacific Growth Fund and find the most important financial news of the day with our companion app Born2Invest.

Europacific Growth Fund has increased its voting rights

According to the information sent to the supervisor, Europacific Growth Fund, which has a total amount of almost 14 million shares in the Spanish firm, “is the legal owner of Grifols shares, and has granted proxy voting authority to Capital Research and Management Company, your investment advisor.”

In fact, Capital Research and Management Company has reduced its participation in Grifols from 4.52% to 4.5%, being divided between 1.42% (6 million shares) of voting rights attributed to the shares and 3 % (13.1 million shares) through financial instruments, specifically, “revocation rights of borrowed ordinary shares.” Thus, Capital Research has a total shareholding package of 19.2 million shares, valued at more than 148 million euros.

Finally, the American bank JPMorgan Chase reduced its stake last Thursday from 5.18% to 3.63% in Grifols after disposing of a share package of almost six million securities valued at around 45 million euros based on current prices. of market .

Grifols shares rose 2.44% around 10:30 in the morning of mArch 18th, until trading its shares at a price of 7.7 euros per share, in a context marked by the movements of bearish funds and by the wait for the analysis of the information required from the blood products company by the National Securities Market Commission (CNMV) after the crisis unleashed by the report published by Gotham City Research.

__

(Featured image by Ibrahim Boran via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us